PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns
Status:
Active, not recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Double-blind, placebo controlled Phase III trial of erythropoietin for hypoxic ischaemic
encephalopathy in infants receiving hypothermia. The study aim is to determine whether Epo in
conjunction with hypothermia in infants with moderate/severe hypoxic ischaemic encephalopathy
(HIE) will improve neurodevelopmental outcomes at 2 years of age, without significant adverse
effects, when compared to hypothermia alone.
Phase:
Phase 3
Details
Lead Sponsor:
University of Sydney
Collaborator:
National Health and Medical Research Council, Australia